CAPR · XBRL financial data

Capricor Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CAPR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	310	245	2,551	25,178	22,270	0
Research and development	8,457	13,571	21,817	36,448	49,969	84,455
General and administrative	5,543	7,612	10,432	12,808	14,867	23,688
Total operating expenses	14,000	21,183	32,249	49,256	64,835	108,142
Operating income (loss)	(13,690)	(20,938)	(29,697)	(24,078)	(42,565)	(108,142)
Interest expense	—	—	—	—	0	3,046
Income tax expense (benefit)	—	—	—	—	2	2
Net income (loss)	(13,657)	(20,023)	(29,020)	(22,288)	(40,467)	(105,044)
Earnings per share, basic USD per share	(0.88)	(0.87)	(1.18)	(0.83)	(1.15)	(2.26)
Earnings per share, diluted USD per share	(0.88)	(0.87)	(1.18)	(0.83)	(1.15)	(2.26)
Weighted average shares, basic thousands of shares	15,571	23,089	24,553	26,778	35,219	46,478
Weighted average shares, diluted thousands of shares	15,571	23,089	24,553	26,778	35,219	46,478

Fiscal years (CAPR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	32,666	34,885	9,603	14,695	11,287	287,847
Marketable securities	—	0	31,818	24,793	140,229	30,282
Prepaid and other current assets	1,011	1,160	920	996	1,501	4,752
Total current assets	33,677	36,437	42,889	50,855	163,385	322,940
Property and equipment, net	851	1,796	4,588	5,561	5,562	18,312
Right-of-use asset	0	2,822	2,350	2,050	1,313	13,538
Total assets	34,619	41,330	50,095	58,734	170,481	355,949
Accounts payable	—	—	—	—	3,284	1,655
Accrued liabilities	—	—	—	—	4,908	15,558
Total current liabilities	2,971	4,133	23,587	31,270	21,026	35,837
Lease liability, non-current	0	2,453	1,878	1,487	616	14,320
Total liabilities	6,419	9,962	38,309	36,133	25,019	50,157
Accumulated deficit	(88,038)	(108,060)	(137,080)	(159,367)	(199,835)	(304,878)
Total stockholders' equity	28,200	31,368	11,786	22,601	145,462	305,792
Total liabilities and equity	34,619	41,330	50,095	58,734	170,481	355,949
Common shares outstanding (cover page) thousands of shares	22,798	24,298	25,255	31,400	45,676	57,511

Fiscal years (CAPR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(13,657)	(20,023)	(29,020)	(22,288)	(40,467)	(105,044)
Stock-based compensation	1,953	2,966	4,459	7,392	9,765	—
Depreciation and amortization	144	246	533	1,069	1,425	1,889
Net cash from operating activities	(10,055)	(16,809)	4,917	(25,597)	(39,996)	(69,811)
Purchases of property and equipment	548	1,196	2,000	1,312	1,167	2,904
Net cash from investing activities	5,439	(1,196)	(35,073)	5,108	(116,184)	97,479
Proceeds from issuing common stock	27,343	20,174	4,804	25,515	152,322	237,034
Share repurchases	0	—	—	—	—	—
Net cash from financing activities	33,382	20,225	4,874	25,580	152,772	248,892

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Capricor Therapeutics	20,935	not reported	(31,485)*	58.1M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Cryoport	269,267	48,971	1,131*	50.6M	—	Q2 FY26 10-QJun 30, 2026
REGENXBIO	36,487	108,019	(62,238)*	66.0M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
CytoDyn	16,359	not reported	(7,726)	1.5B	2.1 quarters	Q1 FY27 10-QAug 31, 2026
Cronos Group	467,019	53,007	24,010*	368.4M	—	Q2 FY26 10-QJun 30, 2026
CytomX Therapeutics	17,224	1,418	(18,068)*	217.9M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Oruka Therapeutics	268,470	not reported	(33,145)*	66.2M	26.4 quarters	Q2 FY26 10-QJun 30, 2026
Theravance Biopharma	219,766	20,731	(6,965)*	51.9M	55.7 quarters	Q2 FY26 10-QJun 30, 2026
Zevra Therapeutics	122,148	37,756	10,047*	59.5M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.